Euro-Med Laboratories Phil., Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 12:08 am EDT
Share
Euro-Med Laboratories Phil., Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was PHP 1,014.96 million compared to PHP 860.19 million a year ago. Net income was PHP 39.02 million compared to PHP 27.39 million a year ago. Basic earnings per share from continuing operations was PHP 0.01 compared to PHP 0.01 a year ago. Diluted earnings per share from continuing operations was PHP 0.01 compared to PHP 0.01 a year ago.
For the six months, sales was PHP 2,139.02 million compared to PHP 1,646.56 million a year ago. Net income was PHP 77.33 million compared to PHP 54.77 million a year ago. Basic earnings per share from continuing operations was PHP 0.02 compared to PHP 0.01 a year ago. Diluted earnings per share from continuing operations was PHP 0.02 compared to PHP 0.01 a year ago.
Euro-Med Laboratories Phil., Inc. is a Philippines-based company, which is engaged in the manufacturing of pharmaceutical products, such as large and small-volume parenteral and other solutions, inhalation, irrigation, and dialysis. It also manufactures sterile water for injection, and other solutions, such as ophthalmic, inhalation, irrigation and dialysis. The Company's segments include manufacturing pharmaceutical products, providing health and other care services, and development and operation of quick service restaurants. Its subsidiaries include Hemotek Renal Center, Inc. (Hemotek), and CafeFrance Corp (CafeFrance). Hemotek provides renal and other healthcare services and is engaged as a dialysis center. CafeFrance is engaged in the development and operation of quick service restaurant (QSR). CafeFrance is engaged in operating restaurants, bakeries, food services, catering, food production and other related services incidental thereto.
EURO-MED LABORATORIES PHIL., INC. 
